Pfizer official. Pfizer (Pfizer) is. Pfizer Cardura for the treatment of patients with symptoms of benign prostatic hyperplasia
Its story begins back in 1849. At the beginning of the last century, the company reached the global level, but continued to develop, regularly offering consumers the latest medications. The article talks about the formation and development of Pfizer, as well as the “Caring for You” project.
Pfizer founded
Today, Pfizer drugs are known all over the world. However, many years ago, when two enterprising young men - Pfizer and Ehart - decided to start their own business, they had neither money nor experience in such matters. However, the first had a diploma in chemistry, and the second was a confectioner.
The father of one of the creators of the Pfizer brand helped with finances. The newly minted businessmen rented a small office in a very modest building located in one of the districts of New York and began to develop the pharmaceutical market.
Santonin
Pfizer's first drug was a drug based on santonin. It was used as an anthelmintic, but had many side effects. It was later replaced by safer drugs. Nevertheless, Pfizer gained instant popularity. The owners of the young company received the medicine as follows: santonin was mixed with almonds.
Lemon acid
In the eighties, Pfizer produced almost no drugs. She concentrated her efforts on At this time, drinks such as Coca-Cola and Pepsi-Cola appeared. As you know, both the first and second contain citric acid, the sale of which determined the growth of the company for many years.
Penicillin
At the beginning of the 20th century, the company established export-import relations. Most of Pfizer's drugs were made based on citric acid. In 1928, A. Fleming conducted a study that revealed the antibiotic properties of penicillin mold.
This discovery became a huge contribution to pharmacology and medicine. Pfizer was now an expert in its field. Most of the antibiotic drugs supplied from the United States during World War II were manufactured under this brand name. In the thirties of the last century, production of B2 was also established. In 1967, production of a broad-spectrum antibiotic, Vibramycin, began, which later became a sales leader.
Pfizer (90s)
In the last decade of the last century, the company established the production and sale of the following products: Zoloft, Azithromycin, Norvasc, Viagra. Once again, Pfizer drugs are gaining popularity. The company receives the status of the most reliable and respected manufacturer in the pharmaceutical world.
Zoloft is a drug that normalizes the functioning of the nervous system. Sertraline is the main active element of this drug, which is a strong antidepressant. Zoloft is taken for panic attacks, social phobia and other nervous disorders. Doctors prescribe Norvasc for arterial hypertension and angina pectoris.
The invention of Viagra was a real event in the world of medicine. As you know, this drug is used in the treatment of erectile dysfunction. The company invested more than three million dollars in developing the drug.
In 1999, the manufacturer celebrated its 150th anniversary. Since the beginning of the new millennium, the Discovery Technology Center has been operating. In addition, as a result of the merger with Warner-Lambert, the company acquired the rights to manufacture and sell a number of medicines.
Pfizer: “Caring for you”
The list of drugs produced under the Pfizer brand is regularly updated. Scientific research and development today is carried out under the leadership of world-class scientists. Pfizer drugs have been present on the Russian market since 1992. Not long ago, the “Caring for You” program was launched, designed to increase the availability of medicines. The rules for participation are quite simple: you need to fill out a form at one of the pharmacies that are partners of the company and receive a discount card. This card can be used to purchase Pfizer products in the future.
Cardiac drugs are included in the list of medicines that Russian consumers have the opportunity to buy at a discount (10-50%). But in reality this list is quite broad. It also includes drugs for the treatment of urological, ophthalmological pathologies, as well as diseases of the nervous system.
To participate in the program, you must have a prescription from a doctor, and only after that fill out a form and receive a card. The range of products eligible for the discount is updated regularly. As an example, below is a list of Pfizer drugs that are subject to discounts in pharmacies of a large Russian chain (“IFK Pharmacy”):
. "Liprimar" is a drug that reduces cholesterol in the blood.
. "Caduet" is a drug intended for the treatment of cardiovascular diseases.
. "Norvasc" is a remedy for the treatment of heart and vascular diseases.
. "Accupro" is a medication used to eliminate arterial hypertension.
. "Accusid" is a drug also intended for the treatment of arterial hypertension.
. Xalatan is a medicine prescribed by an ophthalmologist for the treatment of glaucoma.
The list also includes Viagra, Dalatsin, Inspra, Celebrex, Xalacom. The Caring for You project certainly comes with some limitations. Thus, within the framework of the program, you can purchase at a discount no more than two packages of one of the drugs on the list. Pfizer's partners are pharmacy chains with a total of about 9,000 locations in more than seventy cities in Russia.
American pharmaceutical corporation, which is a leader in the production of drugs for the treatment and prevention of various diseases in all fields of medicine, the company is also engaged in the development and improvement of biotechnologies in the field of pharmaceuticals to combat HIV, for this purpose huge amounts of money are invested in experiments and the production of drugs
Definition of Pfizer, history of development of Pfizer, etymology of the name of Pfizer, management of Pfizer, activities of Pfizer, products of Pfizer drugs, Pfizer in the Russian Federation, financial performance of Pfizer, shares of Pfizer, scandals associated with Pfizer
Pfizer is the definition
Pfizer what is it American pharmaceutical company, one of the largest in the world. The company produces the world's most popular drug, Liprimar (atorvastatin, used to lower cholesterol levels in the blood).
Pfizer, what is it - is it global biopharmaceutical company. Inventor and manufacturer of the world famous drug Viagra.
Pfizer where is it the largest pharmaceutical company, the leader of the global pharmaceutical market, today Pfizer owns a leading portfolio of innovative drugs for the treatment and prevention of various diseases. Pfizer is a leader in developing new drugs to treat diabetes, cancer and cardiovascular diseases.
Pfizer where is it The company, which was founded in 1849 in Brooklyn, is now headquartered in New York. From humble beginnings in the production of fine chemicals, Pfizer has grown into a major pharmaceutical company and a leader in the global pharmaceutical market.
Pfizer is the largest American pharmaceutical corporation, the name of which was given by the name of one of the founders, a German by birth, Charles Pfizer.
Pfizer is An American corporation that is the largest developer and manufacturer of pharmaceutical products in the world and the undisputed leader in the industry.
Pfizer is An American company that started out as a modest fine chemicals company and has grown into one of the largest pharmaceutical companies.
American pharmaceutical corporation Pfizer
Pfizer development history
The history of Pfizer
The company's rapid growth began in 1880 when they produced citric acid. The company continued to purchase property to expand its laboratory and factory on the block bounded by Ballet Street, Harrison Avenue, Gerry Street and Flushing Avenue. These premises are still used as outbuildings. Pfizer established its administrative headquarters at 81 Maiden Lane in Manhattan.
The beginning of the history of Pfizer (1910)
By 1910 (by which time sales had reached $3 million), Pfizer had become a leader in fermentation technology. This knowledge was used to mass produce penicillin during World War II, at the request of the US government. This antibiotic was greatly needed by wounded Allied soldiers; it soon began to be called a “life-giving medicine.” Most of the penicillin that the Allied forces received during the Normandy landings was donated by Pfizer.
The emergence of Pfizer's worldwide distribution network (1950)
By 1950, the company was represented in Belgium, Cuba, Panama, and also in.
Introduction of new technologies by Pfizer (1980-1990)
In the 80s and 90s of the 20th century, the company experienced intense growth, which was associated with sales of new popular drugs.
Acquisition of Warner-Lambert by Pfizer (2000)
In 2000, Pfizer merged with Warner-Lambert and acquired all rights to the drug Lipitor (atorvastatin), previously the market for this drug was divided between Warner-Lambert and Pfizer. Warner-Lambert was located in Morris Plains, New Jersey, now the former headquarters of Pfizer.
Established Products - drugs that have lost patent protection;
Purchase of pharmaceutical giant Wyeth by Pfizer (2009)
On January 26, 2009, Pfizer agreed to buy another giant pharmaceutical company for $68 billion. The deal was completed in October 2009. The largest pharmaceutical industries are GlaxoSmithKline PLC and Pfizer Inc. merged their HIV treatment businesses into a single subsidiary. This is a unique solution, especially for two competing companies. Thus, GlaxoSmithKline and Pfizer hope to breathe new life into the problematic industry, the Journal reports.
Purchase of the Wyeth Company
Experts say the deal shows that pharmaceutical companies are willing to go to any lengths to boost sales when their most promising products suddenly fall out of favor. Glaxo will own 85% of the new corporation, and Pfizer will own 15% of the firm. The new WallStreet is valued at 5 billion (7.5 billion), and from that moment on it owns 19% of the market for HIV drugs.
The British organization GlaxoSmithKline is one of the largest manufacturers of antiretroviral drugs for the treatment of HIV infection in the world. However, it sells drugs that were developed relatively long ago, and this area of the organization is not developing as quickly as we would like. Glaxo has relatively few new developments in HIV treatment.
The American company Pfizer has the opposite situation. It produces relatively few HIV drugs, but has several new drugs against the virus in various stages of development. The organizations hope that by pooling their resources, they will be able to reduce the price of HIV drugs and expand this business, giving it new potential for . The merger reflects a general trend in the modern pharmaceutical industry, which is trying to cope with two major problems, the decline in proprietary drugs and the difficulty in developing new drugs.
On Tuesday, Pfizer shares rose 0.43% to over $30 per share. In recent years, the corporation has begun to develop new markets, primarily offering the well-known drugs Liviton and Viagra. So we can conclude that Pfizer's growth will continue in the near future.
In 2012, the company's sales fell 8% to $57.9 billion, which was due to the availability of generics for a number of its drugs, including the cholesterol-lowering drug Lipitor. It is one of the best-selling drugs in the United States and the world. In 2012, sales of Pfizer's Lipitor fell by 60%. Revenue from sales of Viagra (6th place among the company's best-selling drugs) increased by 4%, to $2.1 billion.
The struggle of the finances of large pharmaceutical companies
Pfizer profitability report
In terms of one share for the half year it amounted to $0.8 versus $0.81 per share a year earlier. Pfizer's revenue at the end of the reporting period decreased by 6%, amounting to $22.72 billion, follows from the American corporation.
The net profit of the pharmaceutical company Pfizer Inc. according to the results of the first half of this year, it decreased by 5% compared to the same period in 2014 and reached $5.002 billion, according to the financial statements of the American corporation.
Net profit per share for the half-year amounted to $0.8 versus $0.81 per share a year earlier. Pfizer's revenue for the reporting period decreased by 6%, amounting to $22.72 billion. At the end of the second quarter, the pharmaceutical giant's net profit decreased by 10% to $2.63 billion, or $0.42 per share ($0.45 a year ago). Pfizer's quarterly revenue was $11.85 billion, down 7%.
The company notes that the second quarter results reflect the continued development of the business and the launch of new products in the US market. Pfizer expects 2015 revenue to be between $45 billion and $46 billion, down from $44 billion to $46 billion previously expected.
Revenue from sales of modified Pfizer drugs
The official press release said that with 11 existing drugs generating $1.6 billion in revenue in 2008, the new firm would have enough financial strength to invest in new developments.
Among the organization's new drugs is an experimental integrase inhibitor, which is currently undergoing the second stage of clinical trials, two new non-nucleoside reverse transcriptase inhibitors, also in the second stage of clinical trials; two CCR5 antagonists, in the first and second stages of clinical trials, as well as one PK enhancer - a representative of a fundamentally new class of drugs, which is now in the first phase of clinical trials.
The official press release states that the organization will develop new fixed-dose combinations of existing drugs and will also develop new drugs. The company intends to invest in the early stages of development and discovery of new substances that could become anti-HIV drugs. The new firm will also have exclusive rights to any new HIV drug developed by GlaxoSmithKline or Pfizer.
This alliance between the two companies is considered unusual in the industry, as major pharmaceutical firms compete with each other over drug sales, attracting talent and bringing new drugs to market. However, this is not the first such case; for example, in 2007, two large organizations entered into a partnership to develop and distribute two anti-diabetes drugs.
One of Pfizer's financial proposals
Pfizer shares
Shares of the North American corporation increased in price by 0.55% and reached $33.17. USA. Pfizer's market capitalization at the beginning of February of this year was a whopping $209.63 billion. USA. I can recommend keeping it in Pfizer; there is every reason to believe that the corporation's assets will grow in the near future. Pfizer shares were included in the industrial calculation base on April 8, 2004
Pfizer scandals
Events that occurred with Pfizer and caused a conflict with one or another side of the business.
Criminal case related to the poisoning of children in Nigeria against Pfizer (1996)
In 1996, as a result of an illegal trial of the drug Trovan in Nigeria (Kano), 11 children died and several dozen became disabled. A criminal case was opened against Pfizer, which ended in a settlement. Subsequently, 546 people filed claims against the company. As a result, experts established the company’s guilt in the deaths of four children (their families were paid compensation of $175 thousand).
Pfizer fined a record $2.3 billion (2009)
In September 2009, in the United States, Pfizer was fined a record $2.3 billion among American pharmaceutical companies for improperly advertising four drugs, the painkiller Bextra, the atypical antipsychotic Geodon (in the Russian Federation it is sold under the name Zeldox (Ziprasidone), the antiepileptic drug Lyrica and antibiotic Zyvox.
Bribery charges against Pfizer subsidiaries (2012)
In August 2012, Pfizer was sentenced to $60 million in the United States, accusing the company of bribery. Two Pfizer subsidiaries were found to have spent more than $2 million in reported bribes between 1997 and 2006. In addition, employees of enterprises that purchased Pfizer drugs could count on a “bonus” of 5% of the transaction amount. The subsidiaries tried to hide these frauds from the parent company. In its official statement, Pfizer argued that if management had known about the methods of its subsidiaries, it would never have approved them.
Pfizer Management
Pfizer management staff and owners. Pfizer management pays great attention and allocates funding to research and development in the field of creating new drugs. The most successful Pfizer drugs were Diflucan - an antifungal drug, Viagra - a drug for the treatment of erectile dysfunction, Geodon - a drug for the treatment of schizophrenia, Vfend - a drug for the treatment of fungal infections, Replax - for the treatment of migraines, Caduet - a drug that lowers cholesterol and high blood pressure, and many other drugs for the treatment of diabetes, cancer, cardiovascular diseases.
The priority direction today is the development of drugs for AIDS and infectious diseases. The constant introduction of new technologies and progressive developments allowed Pfizer to constantly develop and reach new levels; today it is a world leader in pharmacology; the company's shares were included in the Dow Jones calculation, which indicates the influence and success of the company.
Chief manager of the entire management team.
The current board of directors of the organization is as follows - Michael S. Brown, M. Anthony Burns, Robert Barth, Don Cornwell, William H. Gray, Constance Korner, William Howell, Stanley Ikenberry, Jeff Kindler (chairman), George Lorch, Dana Mead , Ruth J. Simmons, William Steere.
Pfizer Chief Legal Officer Jeff Kindler
Chairman of the Board of Pfizer.
Pfizer's activities in the global market
Pfizer is the inventor and manufacturer of the world famous drug Viagra. The production of drugs is carried out at the company's factories located in the USA, Great Britain, Germany, Turkey (46 countries in total). There are representative offices in more than 100 countries, including Russia. The company's main divisions are Human Health, Animal Health and Corporate Groups.
Today we own a leading portfolio of innovative drugs for the treatment and prevention of various diseases. Pfizer is a leader in developing new drugs to treat diabetes, cancer and cardiovascular diseases. The organization annually invests about 7.5 billion dollars in scientific research aimed at creating new effective drugs. The organization operates in more than 150 countries around the world. Research centers are located in England (Sandwich) and the USA (Groton and New England, La Jolla, St. Louis, Rinat, (Massachusetts)).
In order to successfully meet the needs of patients and clients of the company, as well as meet our obligations to shareholders, we constantly improve our business methods, monitor the transparency of the organization’s activities and be sure to take into account the opinions of healthcare experts in making management decisions. We firmly believe that ensuring guaranteed access of the population to the latest medicines and quality medicine can only be achieved through joint work with all parts of the healthcare system - from patients to doctors, from local healthcare institutions to international government and non-governmental organizations.
The company's rapid growth began in 1880 when they began producing citric acid. The organization continued to purchase property to expand its laboratory and factory in the area bounded by Ballet Street, Harrison Avenue, Gerry Street and Flushing Avenue. These premises are still used as outbuildings. Pfizer established its administrative headquarters at 81 Maiden Lane in Manhattan.
Pfizer's sphere of influence
Thanks to continuous progress in the field of medicine and pharmacy, more and more people in the world are able to fight serious diseases, prolonging life and improving health. At the same time, the need for new drugs continues to grow steadily.
Pfizer - life lessons
Pfizer provides high-quality, effective and reliable pharmaceuticals to more than 150 million people every year. By dedicating enormous efforts to developing innovative medicines, Pfizer creates unique products, many of which become significant medical discoveries. Some of the organization's innovative drugs are the only approved drugs against certain serious diseases.
Pfizer and its partners conduct research and development of new medicines in 10 therapeutic areas:
Allergology and respiratory diseases;
Cardiovascular, metabolic and endocrine diseases;
Gastrointestinal and hepatological disorders;
Genitourinary disorders;
Infectious diseases;
Inflammation;
Neurology;
Oncology;
Ophthalmology;
In partnership with other companies and government and non-governmental organizations, Pfizer strives to maximize patient access and awareness of medicines.
Pfizer also cares about animal health. Our Animal Health division is a global leader in the production of veterinary products, annually introducing new products to the market for the treatment and prevention of diseases in both farm and domestic animals.
Pfizer actively collaborates with doctors working in various fields of medicine, providing them with the resources necessary to improve the quality of medical services. We provide detailed information about Pfizer prescription drugs, as well as participation in patient support and research
Pfizer's various drug co-production arrangements
Pfizer Inc. Corporation announced an agreement with the Indian generic organization Aurobindo Pharma Ltd on the production of competitors' drugs that have lost patent exclusivity, The International Herald Tribune reports. David Simmons, head of Pfizer's established products unit, said his firm is committed to effectively reshaping established products.
D. Simmons also said that Pfizer is going to expand its product portfolio through additional cooperation with Aurobindo and other companies. In addition, according to D. Simmons, Pfizer is considering marketing strategies for generic drugs in emerging markets.
According to the terms, Aurobindo will produce and market generic drugs, of which 39 are intended for the US market, 20 for European countries, and an additional 11 for France. In addition, Pfizer will acquire market analysis rights for 12 injectable antibiotics in the US and Europe, including penicillins and cephalosporins. It is not known which drugs will be licensed, but it is known that they will cover a wide range of pharmacotherapeutic classes, including drugs for the treatment of cardiovascular diseases and diseases of the nervous system. According to Pfizer, annual generic drug sales will amount to more than $200 million by 2013. USA. Financial details of the agreement were not disclosed.
Les Funtleyder from Miller Tabak&Co. noted that this is a good initiative that fits well into Pfizer’s recently announced strategy. In addition, it is quite important for the organization to support its division, since generic drugs will play a big role in healthcare reform in the future.
Achievements to improve the production of Pfizer drugs
We list the following achievements:
Successful introduction into clinical practice in the United States of the newest and most promising drug for the treatment of degenerative diseases of the retina Macugen (pegaptanib sodium), which effectively eliminates a number of the main etiopathogenetic factors of blindness (developed jointly with the research company Eyetech Pharmaceuticals, Inc.);
Launch of the antimycotic agent for systemic use Vfend (voriconazole);
FDA approval of the New Drug Application for Exubera (inhaled insulin), a potentially important and promising treatment for patients with both types of diabetes (developed jointly with sanofi-aventis and Nektar Therapeutics);
Significant progress has been made in creating a pipeline of products to complement Pfizer's portfolio; the drug research and development pipeline includes 149 new molecules and 78 projects are underway to improve existing drugs;
Successful optimization of our Human Health Division's operations to better respond to market needs and operate more efficiently and productively will, among other things, enable the Corporation to achieve its $4 billion cost savings target by 2008. US year on year;
Selecting new business approaches to address the most pressing challenges facing healthcare systems in the United States and around the world.
Pfizer's development plans
According to Jeff Kindler, Pfizer no longer intends to depend on the success of a few blockbusters. This is the main reason for the acquisition of the Wyeth Company, one of the first major companies to invest in biotechnology.
Pfizer will focus on biologics vaccines and treatments for Alzheimer's disease and cancer, rather than focusing on conventional drugs such as cholesterol-lowering and antihypertensive drugs (Lipitor, US sales of 13% of the company's total (more than $6 billion) , as well as antidepressants.The company also intends to actively work in the markets of drugs for older people.
Pfizer Working Conditions
Description of the process of personnel training, hiring and doing business in the company.
Pfizer Recruitment
Due to the constant development of the company, personnel selection is carried out throughout the year as vacancies open. The main requirement for candidates for positions related to drug promotion is a higher medical education, while work experience in other companies is not required. For other areas of work, experience in relevant areas is desirable.
Pfizer - 20 years in Russia
Often, when vacancies open, the company tries to fill them using internal reserves, providing its employees with the opportunity for professional and career growth. Preference is given to well-educated, energetic candidates interested in intense work, professional growth and success.
Personnel training at Pfizer
The company has its own professional training department, which allows for intensive training of employees both at the initial stage and during further work. Since the programs are developed not only taking into account the specifics of the Russian market, but also based on global criteria for professionalism, Russian employees acquire an international level of skills and knowledge. Corporate international trainings and seminars are conducted. When conducting training programs, the results of regular employee performance assessments are taken into account.
Pfizer social package
The company offers all its employees a health and life insurance program, as well as social benefits provided for by employment. Expenses for using work and mobile phones are paid. There is a bonus plan based on performance.
To date, more than 100 Pfizer products are registered in Russia. These are drugs for the treatment of diseases of the cardiovascular system, musculoskeletal system, rheumatoid arthritis, urological drugs, drugs for neurology and endocrinology, antibiotics, a wide range of oncological and hematological drugs, vaccines, including pneumococcal vaccine, and vitamins.
Pfizer on the pharmaceutical market of the Russian Federation
Development of the Pfizer company structure in Russia
The history of Pfizer in Russia began in 1992. Then, in the early 90s, the company's top management, trying to make its products available to more people, registered its first Russian representative office. His main task was marketing support and promotion of drugs produced by the company.
In 1995, the first representative office of Pfizer's veterinary division, Pfizer Animal Health, opened in the Russian Federation. Possessing significant potential, the Russian market required a certain flexibility from Pfizer, but such basic moral and ethical principles as loyalty to quality and care for patients remained unchanged.
In 2000, after another summing up of the company’s work, it was decided to increase the number of medical representatives in the Russian Federation. This contributed to the further growth of the company's performance indicators. In 2003, another significant event occurred in the history of Pfizer - after a merger with the pharmaceutical company Pharmacia, Pfizer had the opportunity to expand the portfolio of hospital drugs promoted to the Russian market. By 2007, company representatives were already working in more than 50 cities of the Russian Federation, from Kaliningrad to Vladivostok.
State of the Russian pharmaceutical market
Access to Pfizer drugs for Russian consumers
Thanks to the activities of Pfizer, not only well-known drugs, but also the latest scientific developments have become available to Russian consumers. To date, more than 100 drugs produced by Pfizer are registered in Russia. 14 of them are world leaders in their therapeutic groups. These are drugs for the treatment of diseases of the cardiovascular system, musculoskeletal system, urological drugs, drugs for neurology and endocrinology, antibiotics, a wide range of oncological and hematological drugs.
As a socially oriented company, Pfizer strives to maximize the availability of its drugs to various categories of the population, regardless of income level. To this end, the company actively participates in the provision of preferential medicines, cooperates with the Russian Academy of Medical Sciences, implementing joint projects.
The highly qualified employees of Pfizer, a well-thought-out leadership style, an effective marketing strategy, loyalty to the traditions of quality, commitment to ethical business principles - all this has allowed Pfizer to be one of the leaders in the Russian pharmaceutical market for 18 years. The head of the Pfizer representative office in Russia is Danil Blinov (2011). In 2008, Pfizer LLC was established and the first warehouse of the company's products was opened in Russia (12 km from the Moscow Ring Road). There is no own production in the Russian Federation.
Pfizer products
The company's diversified product portfolio includes biologics, small molecule drugs and vaccines for humans and animals, as well as nutritional products and a range of well-known over-the-counter products worldwide. The organization produces drugs for a wide range of consumers under the well-known brands Benadryl, Sudafed, Listerine, Desitin, Visine, Ben Gay, Lubriderm, Zantac75 and Cortizone. Pfizer is the inventor and manufacturer of the world famous drug Viagra.
The production of drugs is carried out at the company's factories located in the USA, England, France, Italy, Holland, Germany, Turkey (in total - in 46 countries of the world). There are representative offices in more than 100 countries, including the Russian Federation.
Pfizer antibacterial drugs
Drugs with antibacterial effects are used in the treatment of various infectious diseases.
Zyvox Pfizer antimicrobial agent
A synthetic antibacterial drug, it belongs to a new class of antimicrobial agents, oxazolidinones, active in vitro against aerobic gram-positive bacteria, some gram-negative bacteria and anaerobic microorganisms. Linezolid selectively inhibits protein synthesis in bacteria. By binding to bacterial ribosomes, it prevents the formation of a functional 70S initiation complex, which is an important component of the translation process in protein synthesis.
Tazocin Pfizer broad spectrum antibiotic
Piperacillin monohydrate (piperacillin) is a semi-synthetic, broad-spectrum bactericidal antibiotic that is active against many gram-positive and gram-negative aerobic and anaerobic bacteria. Thus, Tazocin combines the properties of a broad-spectrum antibiotic and a beta-lactamase inhibitor.
Tigacil Pfizer antibiotic
The antibiotic tigecycline belongs to the class of glycylcyclines, structurally similar to tetracyclines. Inhibits protein translation in bacteria by binding to the 30S subunit of the ribosome and blocking the penetration of aminoacyl-tRNA molecules into the A-site of the ribosome, which prevents the inclusion of amino acid residues in growing peptide chains. Tigecycline is believed to have bacteriostatic properties.
Pfizer vaccines
A vaccine is a medical or veterinary drug intended to create immunity to infectious diseases. The vaccine is made from weakened or killed microorganisms, their metabolic products, or from their antigens obtained by genetic engineering or chemical means.
Pfizer Prevenar for the prevention of pneumococcal infections
Vaccine for the prevention of pneumococcal infections.
Pfizer drugs used in gynecology
Bottom activity stimulator – prostaglandin E2 analogue. Glucocorticosteroids are prescribed only for hormonal disorders. They are not used as anti-inflammatory drugs in gynecology. For the treatment of female diseases, drugs of the second and third groups are used. Medicines are prescribed for colpitis of various origins, vaginal dysbiosis, inflammatory processes in the uterus, appendages, and fallopian tubes.
Pfizer Prepidil for use during childbirth
Helps in the process of stimulating cervical ripening in the presence of medical and obstetric indications for induction of labor during full-term and near-term pregnancy.
Pfizer drugs used in gastroenterology
The indication for their use in patients with diseases of the gastrointestinal tract is the syndrome of maldigestion and malabsorption of various origins in the presence of exocrine pancreatic insufficiency or without it.
Sab Simplex Pfizer for the treatment of intestines in children
By reducing the surface tension at the phase interface, it impedes the formation and promotes the destruction of gas bubbles in the intestinal contents. The gases released during this process can be absorbed by the intestinal walls or excreted through peristalsis. Prevents interference and overlap of images during sonography and radiography; promotes better irrigation of the colon mucosa with a contrast agent, preventing rupture of the contrast film. Simethicone changes the surface tension of gas bubbles formed in the contents of the stomach and intestinal mucus and causes their destruction. The released gases are absorbed by the intestinal wall or removed by intestinal peristalsis. Simethicone removes foam physically and does not enter into chemical reactions.
Pfizer's Sab Simplex
Pfizer drugs used in cardiology
With high blood pressure, the heart works overload, the mass of the heart muscle increases, and hypertrophy of the left ventricle of the heart develops. Also, the vessels of the heart, brain, kidneys, and retina work with overload. Over time, patients with high blood pressure develop cardiovascular complications: myocardial infarction, stroke, hemorrhages in the fundus. Currently, very effective and safe drugs have been created that lower blood pressure, which not only reduce blood pressure to the required levels, but also prevent the development of cardiovascular complications. The medications are selected by the attending physician. The course of treatment is lifelong.
Accusid Pfizer heart drug
Combination antihypertensive drug (diuretic + angiotensin-converting enzyme inhibitor).
Accupro Pfizer to improve blood circulation
Quinapril increases exercise tolerance. With long-term use, it promotes the reverse development of myocardial hypertrophy in patients with arterial hypertension, improves blood supply to ischemic myocardium. Strengthens coronary and renal blood flow. Reduces platelet aggregation.
Inspra Pfizer treatment of heart disease
Eplerenone causes a persistent increase in the concentration of renin in the blood plasma and aldosterone in the serum. Subsequently, renin secretion is inhibited by aldosterone via a feedback mechanism. However, an increase in renin activity or circulating aldosterone concentration does not affect the effects of eplerenone.
Caduet Pfizer for the treatment of combined cardiovascular diseases
KADUET® is a combination drug intended for the treatment of concomitant cardiovascular diseases (arterial hypertension/angina pectoris and dyslipidemia).
Liprimar Pfizer lipid-lowering drug
Atorvastatin is a selective competitive inhibitor of HMG-CoA reductase, a key enzyme that converts 3-hydroxy-3-methylglutaryl-CoA into mevalonate, a precursor to steroids, including cholesterol, a synthetic lipid-lowering agent.
Norvasc Pfizer for cardiovascular disorders
In patients with cardiovascular diseases (including coronary atherosclerosis with damage to one vessel and up to stenosis of 3 or more arteries and atherosclerosis of the carotid arteries), who have had myocardial infarction, percutaneous transluminal angioplasty of the coronary arteries (PTA) or suffering from angina, the use of Norvasc prevents the development of thickening of the intima-media of the carotid arteries, significantly reduces mortality from cardiovascular causes, myocardial infarction, stroke, TLP, coronary artery bypass grafting, leads to a decrease in the number of hospitalizations for unstable angina and progression of chronic heart failure (CHF), reduces the frequency of interventions, aimed at restoring coronary blood flow.
RevatioPfizer to lower blood pressure
The film-coated tablets are white or off-white, round, biconvex, debossed with “RVT 20” on one side and “Pfizer” on the other side.
Pfizer drugs used for lincosamide
Lincosamides are a group of antibiotics that includes the natural antibiotic lincomycin and its semisynthetic analogue clindamycin. They have bacteriostatic or bactericidal properties depending on the concentration in the body and the sensitivity of microorganisms.
Pfizer Champix for treating smoking addiction
Patients who are unwilling or unable to set a goal to quit smoking within 1-2 weeks can be offered treatment, with the option of choosing their own quit date within 5 weeks. Patients who had previously attempted to quit smoking with varenicline and who were re-treated with varenicline had better rates of confirmed sustained abstinence compared with placebo.
Champix Pfizer
Pfizer drugs used in ophthalmology
Ophthalmology is a field of medicine that studies the eye, its anatomy, physiology and diseases, as well as developing methods for the treatment and prevention of eye diseases.
Pfizer's Xalacom for the treatment of intraocular pressure
The mechanism for reducing elevated intraocular pressure (IOP) is different for these components, which provides an additional reduction in IOP compared to the effect achieved when using each of these components as monotherapy.
Pfizer Xalatan for the prevention of intraocular pressure
Reduces elevated intraocular pressure (IOP) in adults and children (over 1 year of age) with open-angle glaucoma or increased ophthalmotonus.
Pfizer drugs used in oncology
Oncological diseases are a large and heterogeneous class of diseases. Oncological diseases are systemic and affect, in one way or another, all human organs and systems. There are many forms and options for cancer treatment. Although patients often perceive an oncological diagnosis as a death sentence, not all even malignant tumors lead to death. Modern research has demonstrated that every person regularly develops cancer cells and microtumors in their body, which die and are resolved under the influence of the antitumor immune system.
Psychoneurology, a complex of sciences about human behavior. In the understanding of some authors, this concept includes anatomy and physiology of the nervous system, neuropathology, psychiatry and mental hygiene, psychology, psychotechnics, pedology, and a complex of sciences about human behavior. In the understanding of some authors, this concept includes anatomy and physiology of the nervous system, neuropathology, psychiatry and mental hygiene, psychology, psychotechnics, pedology, and a complex of sciences about human behavior. In the understanding of some authors, this concept includes anatomy and physiology of the nervous system, neuropathology, psychiatry and mental hygiene, psychology, psychotechnics, and pedology.
Zeldox Pfizer antipsychotic drug for the treatment of schizophrenia
Pharmacotherapeutic group, antipsychotic (neuroleptic). Treatment of schizophrenia. The drug is effective in the treatment of productive and negative symptoms, as well as affective disorders.
Zoloft Pfizer antidepressant
Antidepressant, a powerful specific inhibitor of serotonin (5-HT) reuptake in neurons. It has a very weak effect on the reuptake of norepinephrine and dopamine. At therapeutic doses, sertraline blocks the uptake of serotonin into human platelets. It does not have stimulant, sedative or anticholinergic effects.
Pfizer's Lyrica for the treatment of epilepsy patients
The active ingredient is pregabalin, an analogue of gamma-aminobutyric acid ((S)-3-(aminomethyl)-5-methylhexanoic acid). The pharmacokinetic parameters of pregabalin at steady state in healthy volunteers, in patients with epilepsy receiving antiepileptic therapy, and in patients receiving it for chronic pain syndromes were similar.
Lyrica Pfizer
Relpax Pfizer anti-migraine drug
The antimigraine drug Eletriptan is a member of a group of selective agonists of serotonin vascular 5-HT1B and neuronal 5-HT1D receptors. Eletriptan also has high affinity for 5-HT1F serotonin receptors and has moderate effects on 5-HT1A, 5-HT2B, 5-HT1E and 5-HT7 serotonin receptors.
Sermion Pfizer to improve blood circulation in the brain
An ergoline derivative improves metabolic and hemodynamic processes in the brain, reduces platelet aggregation and improves hemorheological blood parameters, increases the speed of blood flow in the upper and lower extremities. Nicergoline exhibits an α1-adrenergic blocking effect, leading to improved blood flow and has a direct effect on the cerebral neurotransmitter systems - noradrenergic, dopaminergic and acetylcholinergic.
Antifungals are drugs used to treat infections such as athlete's foot, ringworm, candidiasis (thrush), serious systemic infections such as cryptococcal meningitis and others. These drugs can usually be obtained with a doctor's prescription or purchased without a prescription.
Pfizer's Vfend is a broad-spectrum antifungal drug
A broad-spectrum antifungal drug from the triazole group. The mechanism of action of voriconazole is associated with inhibition of 14α-sterol demethylation mediated by fungal cytochrome P450, a key step in ergosterol biosynthesis.
Diflucan Pfizer antifungal agent
Fluconazole, a triazole antifungal agent, is a potent selective inhibitor of sterol synthesis in fungal cells. When administered orally and intravenously, fluconazole was active in various animal models of fungal infections.
Pfizer's Diflucan
Rheumatology is a specialization of internal medicine that deals with the diagnosis and treatment of rheumatic diseases. The term “rheumatology” itself comes from the Greek word “ρεύμα”, meaning “stream, river” and the suffix “-logos”, meaning “study”. The subject of study of rheumatology is inflammatory and degenerative-dystrophic diseases of the joints and systemic diseases of connective tissue (the outdated name is collagenosis).
Celebrex Pfizer anti-inflammatory drug
Non-steroidal anti-inflammatory drug (NSAID). Celecoxib has anti-inflammatory, analgesic and antipyretic effects by blocking the formation of inflammatory prostaglandins (Pg) mainly through inhibition of cyclooxygenase-2 (COX-2). Induction of COX-2 occurs in response to inflammation and leads to the synthesis and accumulation of prostaglandins, especially prostaglandin E2, with increased manifestations of inflammation (swelling and pain).
Enbrel Pfizer for arthritis
Tumor necrosis factor (TNF-α, TNF) is the main cytokine that supports the inflammatory process in rheumatoid arthritis. Increased levels of TNF were also found in the synovial membranes and psoriatic plaques of patients with psoriatic arthritis, as well as in the plasma and synovial tissues of patients with ankylosing spondylitis.
The field of surgery and cardiology, eliminating pathologies of the cardiovascular system. In particular, cardiac surgery is the most effective method of treating coronary artery disease, preventing the development of myocardial infarction.
Fragmin Pfizer anticoagulant agent
Direct acting anticoagulant. Dalteparin sodium is a low molecular weight heparin isolated by controlled depolymerization (with nitrous acid) of sodium heparin from the mucous membrane of the small intestine of pigs and subjected to further purification using ion exchange chromatography.
Transplantology is a branch of medicine that studies the problems of organ transplantation (in particular, kidneys, liver, heart), as well as the prospects for creating artificial organs.
Rapamune Pfizer strong pain reliever
Sirolimus inhibits T-lymphocyte activation by blocking calcium-mediated and calcium-independent intracellular signaling. Research data suggest that the mechanism of action of sirolimus is different from that of cyclosporine, tacrolimus and other immunosuppressants. According to experimental data, sirolimus binds to a specific cytosolic protein - immunophilin.
Urology is a field of clinical medicine that studies the etiology, pathogenesis, diagnosis of diseases of the urinary system, male reproductive system, diseases of the adrenal glands and other pathological processes in the retroperitoneal space and develops methods for their treatment and prevention.
Viagra Pfizer for sexual stimulation
A powerful selective inhibitor of cycloguanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). The physiological mechanism of erection is associated with the release of nitric oxide (NO) in the corpus cavernosum during sexual stimulation. This, in turn, leads to an increase in the level of cGMP, subsequent relaxation of the smooth muscle tissue of the corpus cavernosum and an increase in blood flow. A prerequisite for the effectiveness of sildenafil is sexual stimulation.
Viagra Pfizer
Pfizer Detrusitol for Bladder Treatment
It is a competitive antagonist of cholinergic muscarinic receptors with the greatest selectivity for bladder receptors. The 5-hydroxymethyl derivative of tolterodine is also highly specific for muscarinic receptors and has no significant effect on other receptors. Tolterodine reduces detrusor contractility and also reduces salivation. In doses exceeding therapeutic doses, it causes incomplete emptying of the bladder and increases the amount of residual urine.
Pfizer Cardura for the treatment of patients with symptoms of benign prostatic hyperplasia
Prescribing doxazosin to patients with symptoms of benign prostatic hyperplasia (BPH) leads to a significant improvement in urodynamics and a decrease in the manifestations of symptoms of the disease.
Endocrinology is the science of the structure and function of the endocrine glands (endocrine glands), the products they produce (hormones), the ways of their formation and action on the body of animals and humans; as well as diseases caused by dysfunction of these glands or the action of these hormones. Endocrinology is one of the youngest and fastest growing branches of medicine, dealing with the treatment of diseases associated with disorders of the endocrine system. Problems of endocrinology, to one degree or another, affect almost all areas of medicine and are closely related to cardiology, oncology, ophthalmology, gastroenterology, nephrology, neurology, and gynecology.
Dostinex Pfizer for the treatment of thyroid disorders
Cabergoline is a dopaminergic derivative of ergoline and is characterized by a pronounced and long-lasting prolactin-lowering effect due to direct stimulation of D2-dopamine receptors of lactotropic cells of the pituitary gland.
Sources and links
Sources of texts, pictures and videos
wikipedia.org - free encyclopedia collection of Wikipedia terms
academic.ru - information and analytical site about the term
ubr.ua - site of analytics and news about companies and business
Pfizer.ru - information portal about Pfizer
vnutri.org - analytical news site Inside
brandpedia.ru - site of analytics and articles all available about companies
evolutsia.com - news and analytics site Evolution
cosmomir.ru - information portal Cosmomir
wapedia.mobi - information site for news and articles from Wapedia
apteka.ua - article portal All about pharmaceutics
Ua - Any purchase of a navel with a discount on the information site
works.tarefer.ru - portal collection of abstracts and reports
grandars.ru - information and analytical portal
catback.ru - information and analytical site about the term
en.academic.ru - site collection of articles and terms
akm.ru - economic information agency on the portal
allendy.ru - economic portal on economics
Bloomberg .com - information and analytical agency
catback.ru - scientific articles and educational materials on economics
Pfizer.com - official website of Pfizer
finance_investment.academic.ru - financial and investment portal
glav-love.ru - business news and analytics website
cosmomir.ru - site of news and articles from various companies
proactions.ru - information and analytical news portal
ambar.ua - portal of products and range of companies
medi.ru - site for analytics and information about it
expertoza.com - news and analytics site
pidruchniki.com - portal collection of books and articles
chipsaway.ua - news and analytics site about economic terms
homearchive.ru - information and analytical portal about business
financial-lawyer.ru - financial analytical site
5ballov.qip.ru - business analytics and news site
amerikos.com - website of American news and analytics
glamlemon.ru - products and articles on the portal
directory.paininfo.ru - website for pharmaceuticals and analytics about it
Pfizer.ru - official website of Pfizer in the Russian Federation
Links to Internet services
forexaw.com - information and analytical portal on financial markets
Ru - the largest search engine in the world
video.google.com - search for videos on the Internet using Google
play.google.com - various applications on the Internet
docs.google.com - document storage and exchange service
translate.google.ru - search engine translator
Google youtube.com - search for video materials on the largest portal in the world
Ru is the largest search engine in the Russian Federation
wordstat.yandex.ru - a service from Yandex that allows you to analyze search queries
video.yandex.ru - search for videos on the Internet via Yandex
images.yandex.ru - search for images through the service
Yandex ru.tradingeconomics.com - service of economic data of countries of the world
Article creator
Odnoklassniki.Ru/profile/459752031180 - profile of the author of this article in Odnoklassniki
Plus.Google.Com/u/0/104482530940845863083/posts - profile of the author of the material on Google+
My.Mail.Ru/Mail/miroshnichenko.b.o - profile of the author of this material in My World
-Mergers and Acquisitions - Warner-Lambert / Parke-Davis / Agouron - Owners and Management
Activity
Pfizer in the Russian Federation -Company Pfizer(USA) -Reorganization of the organization Development plans -Scandals
Field of activity
Agreements
Pfizer, Inc. - This American pharmaceutical organization, one of the largest in the world. Firm produces the world's most popular drug Lipitor (Atorvastatin, used to lower blood cholesterol levels). Also sells the following popular drugs: Lyrica, Diflucan, Zithromax, Viagra, Celebrex. Pfizer shares were included in the Dow Jones Industrial Average on April 8, 2004. Headquarters are located in New York City, and the main research center is in Groton, Connecticut.
Story
Pfizer was founded in 1849 in Brooklyn and is now headquartered in New York. From humble beginnings in the production of fine chemicals, Pfizer has grown into a major pharmaceutical organization and a leader in the global pharmaceutical market.
Today we own a leading portfolio of innovative drugs for the treatment and prevention of various diseases. Pfizer is a leader in developing new drugs to treat diabetes, cancer and cardiovascular diseases. The organization annually invests about $7.5 billion in research aimed at creating new effective drugs. The organization operates in more than 150 countries around the world. Research centers are located in England (Sandwich) and USA(Groton and New England, La Jolla, St. Louis, Rinat, (Massachusetts)).
In order to successfully meet the needs of patients and clients of the company, as well as meet our obligations to shareholders, we constantly improve our business methods, monitor the transparency of the organization’s activities and be sure to take into account the opinions of healthcare experts in the process of making management decisions. We firmly believe that ensuring guaranteed access of the population to the latest medicines and quality medicine can only be achieved through joint work with all parts of the healthcare system - from patients to doctors, from local healthcare institutions to international governmental and non-governmental organizations.
By 1910, with sales reaching $3 million, Pfizer was considered an expert in fermentation technology. This knowledge was used to mass produce penicillin during World War II, at the request of the government USA. This antibiotic was greatly needed by wounded Allied soldiers; it soon began to be called a “life-giving medicine.” Most of the penicillin that Allied forces received at the Normandy Landings was provided by Pfizer.
By 1950, the organization was represented in Belgium, Brazil, Canada, Cuba, Iran, Mexico, Panama, Puerto Rico, Turkey, and Britain.
In the 80s and 90s of the 20th century, the company experienced intensive growth, which was associated with the invention and sales new popular drugs.
In 2005, Pfizer was one of 53 companies that supported the inauguration of George W. Bush with a maximum amount of $250,000.
Mergers and acquisitions Warner-Lambert / Parke-Davis / Agouron
In 2000, Pfizer merged with Warner-Lambert and acquired all rights to the drug Lipitor (atorvastatin), previously market of this drug was divided between Warner-Lambert and Pfizer. Warner-Lambert was located in Morris Plains, New Jersey, now a major base of operations for the Pfizer organization. Most of Pfizer's manufacturing facilities, as well as its Consumer Healthcare division (worth $3.87 billion in 2005), were sold to Johnson & Johnson in 2006 for $16.6 billion.
Parke-Davis was absorbed by Warner-Lambert in 1970, which in turn was absorbed by Pfizer in 2000. The Parke-Davis headquarters was sold several years ago. Pfizer sold the massive Parke-Davis research complex to the University of Michigan in 2008 for $108 million.
On January 26, 2009, Pfizer agreed to buy another giant pharmaceutical firm. Wyeth for $68 billion. The deal was completed in October 2009.
The largest pharmaceutical companies are GlaxoSmithKline PLC and Pfizer Inc. merged their HIV treatment businesses into a single subsidiary. This is a unique solution, especially for two competing companies. Thus, GlaxoSmithKline and Pfizer hope to breathe new life into a problematic segment market, reports the Wall Street Journal. According to experts, deal demonstrates that pharmaceutical organizations are willing to go to any lengths to increase sales, when their most promising products suddenly fall out of favor. Glaxo will own 85% of the new corporation, and Pfizer will own 15% of the firm. The cost of the new Wall Street is estimated at £5 billion (7.5 billion dollars), and from that moment on it owns 19% of the market for anti-HIV drugs.
The British organization GlaxoSmithKline is one of the largest manufacturers of antiretroviral drugs for the treatment of HIV infection in the world. However, it sells drugs that were developed relatively long ago, and this area of the organization is not developing as quickly as we would like. Glaxo has relatively few new developments in HIV treatment.
The American company Pfizer has the opposite situation. It makes relatively few drugs against HIV, but it has several new drugs against the virus in various stages of development. Organizations hope that by pooling their resources they can reduce prices for anti-HIV drugs and expand this business, giving it new potential for development. The merger reflects a broader trend in the modern pharmaceutical industry, which is struggling to cope with two major problems: declining revenue from brand-name drugs and difficulties in developing new drugs.
In an official press release, Andrew Witty, chief executive officer of Glaxo, said: “Today marks the day GlaxoSmithKline takes a step forward to renew our commitment to produce more medicines with greater effectiveness for people living with HIV/AIDS. At the heart of this dedicated organization is a portfolio of products and new developments that will be more effectively exploited thanks to the new firm's strong sales base and research capabilities. This new firm is better positioned to meet existing challenges and increase access to treatment."
Jeff Kindler, Chief Executive Officer of Pfizer, said: “By combining the complementary strengths and capabilities of Pfizer and GlaxoSmithKline, we will create a new global leader in HIV and reaffirm our commitment to treating HIV. diseases. The organization has a broad portfolio of HIV treatment products and is strengthened by Pfizer's HIV development resources and GlaxoSmithKline's global drug distribution capabilities, giving the organization the ability to bring new and improved medicines to patients as quickly and efficiently as possible. efficiency. The new organization can reach more patients and achieve more in the global HIV treatment space than either of our companies could do individually.”
“I think this is an example of trying to deal with existing problems,” said Andrew Whitty during a press conference. “You can see a new generation of management that is ready to look for new solutions.” Whitty became chief executive last year. Jeffrey Kindler became chief executive officer in 2006.
The company's combined businesses achieved sales of 1.6 billion dollars last year and their profit from operations is £870 million. Analysts usually estimate that such an organization's sales will increase two to three times, so the new company is valued at $4-5 billion.
Agenerase (amprenavir), a protease inhibitor.
Combivir (zidovudine and lamivudine), a nucleoside reverse transcriptase inhibitor.
Epivir (lamivudine, 3TC), a nucleoside reverse transcriptase inhibitor.
Epzicom (Kivexa, abacavir and lamivudine), a nucleoside reverse transcriptase inhibitor.
Retrovir (zidovudine, AZT), a nucleoside reverse transcriptase inhibitor.
Levixa (Telzir, fosamprenavir), a protease inhibitor.
Rescriptor (delavurdine), a non-nucleoside reverse transcriptase inhibitor (USA only).
Celsentri (Celsentri, maraviroc), a CCR5 antagonist.
Trizivir (abacavir, zidovudine and lamivudine), a nucleoside reverse transcriptase inhibitor.
Viracept (nelfinavir), a protease inhibitor (available in North America only).
Ziagen (abacavir), a nucleoside reverse transcriptase inhibitor.
The new company will also continue to develop and test 6 new drugs. In the official press release It said that with 11 existing drugs generating $1.6 billion in revenue in 2008, the new firm would have enough financial strength to invest in new developments.
Among the organization's new drugs is an experimental integrase inhibitor, which is currently undergoing the second stage of clinical trials; two new non-nucleoside reverse transcriptase inhibitors, also in phase 2 clinical trials; two CCR5 antagonists, in phase 1 and 2 clinical trials; as well as one PK amplifier - a representative of a fundamentally new class of drugs, which is currently in the first phase of clinical trials.
In the official press release It said the organization will develop new fixed-dose combinations of existing drugs and will also develop new drugs. intends to invest in the early stages of development and discovery of new substances that can become drugs against HIV. The new firm will also have exclusive rights to any new HIV drug developed by GlaxoSmithKline or Pfizer.
This alliance between the two companies is considered unusual in the industry, as large pharmaceutical firms compete fiercely with each other to sell drugs, attract talent and bring new drugs to market. However, this is not the first such case; for example, in 2007, two large organizations entered into a partnership to develop and distribute two anti-diabetes drugs.
home profit Such an alliance will result in a reduction in the enormous risk associated with the development of new drugs. Clinical trials can cost hundreds of millions of dollars, with many drugs proving ineffective or unsafe. HIV is considered a very risky area to invest in new developments. There are already more than 20 good and effective drugs, and coming up with something better than them is not an easy task.
Both firms had previously been harshly criticized by HIV activists for being too expensive. prices on drugs in both rich and poor countries. This pressure has forced organizations to reduce prices over the past few years, and in the poorest countries prices around the world have dropped to non-commercial levels.
Recently, the HIV treatment business has begun to slow GlaxoSmithKline's overall sales growth. Sales of HIV drugs were up 5% from 2007, while the firm's overall sales were up 7%. So Pfizer needs new developments to “stay in the game,” as Whitty says.
The chief executive officer of the new organization will be Dominique Limet, who worked for many years at GlaxoSmithKline. French physician, Dr. Limet headed work personalized drug companies
Owners and management
Chairman of the Board of Directors and CEO is Jeff Kindler.
The organization's current board of directors is as follows: Michael S. Brown, M. Anthony Burns, Robert Barth, Don Cornwell, William H. Gray, Constance Corner, William Howell, Stanley Ikenberry, Jeff Kindler (chairman), George Lorch, Dana Mead, Ruth J. Simmons, William Steere.
Activity
The organization produces drugs for a wide range of consumers under the well-known brands Benadryl, Sudafed, Listerine, Desitin, Visine, Ben Gay, Lubriderm, Zantac75 and Cortizone. Pfizer is the inventor and manufacturer of the world famous drug Viagra.
The production of drugs is carried out at the company’s factories located in the USA, England, France, Italy, Holland, Germany, Turkey(in total - in 46 countries of the world). There are representative offices in more than 100 countries, including Russian Federation.
According to the British information and publishing agency URCH Publishing, Pfizer is the leader in the global pharmaceutical market (2007) with a market share of 6.2% (closest competitors: GSK - 5.4%, Roche - 4.3%). The organization's main divisions are Human Health, Animal Health and Corporate Groups.
The total number of personnel (at the end of 2008) is 83 thousand people (106 thousand people in 2005).
Annual sales in 2008 were $48.3 billion ($48.4 billion in 2007, $51.3 billion in 2005). The company's profit is $8.1 billion ($8.14 billion in 2007).
Pfizer at Russian Federation
The head of the Pfizer representative office in the Russian Federation is Christian Holmer (since October 2009).
In 2008, a legal entity was established. the face of Pfizer LLC and the first warehouse of the company’s products was opened in the Russian Federation (12 km from the Moscow Ring Road). There is no own production in the Russian Federation.
Pfizer Company (USA)
In 2000, a new united organization was formed from two companies - leaders in the pharmaceutical business - Pfizer and Warner-Lambert through a merger.
The company's activities are aimed at developing drugs to combat the most severe and common ailments of mankind:
Cardiovascular diseases (Norvasc, Accupro, Liprimar),
Impotence (Viagra),
Severe infections (Cephobid and Sulperazone),
Systemic candidiasis (Diflucan),
Prostate adenoma (Kardura),
Depression (Zoloft).
The range of products is very wide.
The organization's portfolio also includes over-the-counter OTC drugs - the well-known Vizin, Tizin, Ben-Gay, Bonin, Desitin and relatively new products produced by Parke-Davis (a division of Warner-Lambert): Hexoral, Olint, Sub Simplex
Organization reorganization
At the end of 2008 and beginning of 2009, Pfizer underwent a reorganization, new business units were created that were more clearly focused on customers:
Pfizer Oncology, which develops and markets oncology drugs;
Emerging Markets, which brings together the developing markets of Europe, Latin America, Africa, the Middle East, and Asia;
Established Products, responsible for off-patent drugs;
Specialty Care, etc.
In November 2008, an independent research unit, Pfizer Regenerative Medicine Research Unit, was opened to study the nature of stem cells and their potential use in the treatment of degenerative diseases.
Development plans
According to Jeff Kindler, Pfizer no longer intends to depend on the success of a few blockbusters. This is the main reason agreement to acquire the company, one of the first large companies to invest in biotechnology.
Pfizer will focus on biologics vaccines and treatments for Alzheimer's disease and cancer, rather than focusing on conventional drugs such as cholesterol-lowering and antihypertensive drugs (Lipitor, US sales of 13% of the organization's total, more than $6 billion) drugs, as well as antidepressants.The organization also intends to actively work in the markets of drugs for older people.
Until 2014, the company's brands such as the cholesterol-lowering drug Lipitor, the antihypertensive drug Norvasc, the erectile dysfunction drug Viagra and the glaucoma treatment Xalatan will lose patent protection. Annual consolidated sales of these drugs are $16.7 billion
Scandals
In 1996, an illegal trial of the antibiotic Trovan in Nigeria ( state Kano) 11 children died. A criminal case was initiated against Pfizer, which ended in a settlement agreement
Field of activity
Thanks to continuous progress in the field of medicine and pharmacy, more and more people in the world are able to fight serious diseases, prolonging life and improving health. At the same time, the need for new drugs continues to grow steadily.
Pfizer provides high-quality, effective and reliable pharmaceuticals to more than 150 million people every year. By dedicating enormous efforts to developing innovative medicines, Pfizer creates unique products, many of which become significant medical discoveries. Some of the organization's innovative drugs are the only approved drugs against certain serious diseases.
Pfizer and its partners conduct research and development of new medicines in 10 therapeutic areas:
Allergology and respiratory diseases,
Cardiovascular, metabolic and endocrine diseases,
Gastrointestinal and hepatological disorders,
Genitourinary disorders
Infectious diseases,
Inflammation,
Neurology,
Oncology,
Ophthalmology,
In partnership with other companies and government and non-governmental organizations, Pfizer strives to maximize patient access and awareness of medicines.
Pfizer also cares about animal health. Our Animal Health division is a global leader in the production of veterinary products, annually introducing new products to the market for the treatment and prevention of diseases in both farm and pet animals.
Pfizer actively collaborates with doctors working in various fields of medicine, providing them information and resources needed to improve the quality of health services. We provide detailed information about Pfizer prescription drugs, as well as participation in patient support programs and research
Agreements
Pfizer Inc. announced an agreement with the Indian generic organization Aurobindo Pharma Ltd to produce and license the latter's drugs from competitors that have lost patent exclusivity, The International Herald Tribune reports. David Simmons, head of Pfizer's established products unit, said his firm is committed to effectively reshaping established products.
D. Simmons also said that Pfizer is looking to expand its product portfolio through additional collaborations with Aurobindo and other companies. In addition, according to D. Simmons, Pfizer is considering marketing strategies for generic drugs in emerging markets.
Under the terms of the concession, Aurobindo will produce and market generic drugs, of which 39 are intended for the US market, 20 for European countries, and an additional 11 for France. In addition, Pfizer will acquire the rights to analyze market conditions for 12 injectable antibiotics in the US and Europe, including penicillins and cephalosporins. It is not known which drugs will be licensed, but it is known that they will cover a wide range of pharmacotherapeutic classes, including drugs for the treatment of cardiovascular diseases and diseases of the nervous system. According to Pfizer forecasts, annual sales of generic drugs will amount to more than $200 million by 2013. USA. Financial details of the agreement were not disclosed.
Loading...
